Gene Therapy Breakthrough: Antigen-Specific Cytotoxic T Lymphocyte Therapy Shows Promising Results

Strategic Insights -

Research published in Frontiers in Immunology has revealed a promising breakthrough in gene therapy, highlighting the potential of antigen-specific cytotoxic T lymphocyte (ACTL) therapy in overcoming resistance to chemotherapy and targeted therapy in advanced lung cancer patients. The study, led by researchers from the First Affiliated Hospital of Nanjing Medical University, describes a patient who achieved a clinical complete response after receiving ACTL therapy, marking the first reported case of a "clinical cure" in a patient with acquired resistance to EGFR-TKI therapy.

Key Takeaways:

  • The study describes a patient with IVa stage advanced lung adenocarcinoma who developed acquired resistance to EGFR-TKI therapy with an unknown mechanism and was in an immune-suppressed state.
  • The patient received ACTL therapy and achieved a clinical complete response (cCR) and maintained it for six years of follow-up, marking the first reported case of a "clinical cure" in a patient with acquired EGFR-TKI resistance.
  • ACTL therapy has demonstrated potential in overcoming targeted resistance in advanced lung cancer and inducing deep remission by reshaping the tumor immune microenvironment (TME).
  • The study highlights the novel cellular immunotherapy approach of ACTL, which combines target precision and immune balance, as a potential solution for overcoming targeted resistance in advanced lung cancer.
  • The research team, led by Chenghao Fu and including Chengyu Bian, Weiyou Zhu, Haonan Du, Linrui Han, Jian Zhu, Jun Wang, and Lei Cao, has published their findings in the journal Frontiers in Immunology, volume 16, 2025.

Statistics:

  • The patient achieved a clinical complete response (cCR) and maintained it for six years of follow-up.
  • The study highlights the first reported case of a "clinical cure" in a patient with acquired EGFR-TKI resistance.
  • The number of patients with advanced lung adenocarcinoma with acquired EGFR-TKI resistance is estimated to be a significant proportion of the total population of patients with advanced lung cancer.

Sources:

  • "Case Report: Durable complete response to antigen-specific cytotoxic T lymphocyte therapy in advanced EGFR-TKI resistant lung adenocarcinoma: a case of adoptive cellular immunotherapy overcoming acquired targeted resistance" (Frontiers in Immunology, 2025,16) by Chenghao Fu, Chengyu Bian, Weiyou Zhu, Haonan Du, Linrui Han, Jian Zhu, Jun Wang, Lei Cao.
  • Frontiers in Immunology (journal - http://journal.frontiersin.org/journal/immunology).
  • Biotech Week (newspaper - September 17, 2025; p 164).